抗黑素瘤分化相关基因5抗体阳性皮肌炎治疗进展

doi:10.35541/cjd.20220368

Abstract

Abstract: 【Abstract】 Anti-melanoma differentiation-associated gene 5 （MDA5） antibody-positive dermatomyositis is a special type of dermatomyositis. It has characteristic clinical manifestations, mild myositis symptoms, and is prone to be accompanied by rapidly progressive interstitial lung disease, which indicates a poor prognosis. Its pathogenesis remains unclear, and may be related to genetic and environmental factors. This review summarizes progress in the treatment of anti-MDA5 antibody-positive dermatomyositis in recent years, in order to provide new ideas for its clinical treatment.

Key words: Dermatomyositis, Immunosuppressive therapy, Melanoma differentiation-associated gene 5, Anti-melanoma differentiation-associated gene 5 antibody, Interstitial lung disease

Zhan Jinshan, Xuan Xiuyun, Cao Juanmei, Chen Fangqi, Huang Changzheng. Progress in treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis[J]. Chinese Journal of Dermatology,2023,e20220368. doi:10.35541/cjd.20220368

References ［29］

［1］	Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation⁃associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease［J］. Arthritis Rheum, 2009,60（7）:2193⁃2200. doi: 10.1002/art.24621.
［2］	Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment［J］. J Am Acad Dermatol, 2020,82（2）:283⁃296. doi: 10.1016/j.jaad.2019.05.105.
［3］	Nombel A, Fabien N, Coutant F. Dermatomyositis with anti⁃MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies［J］. Front Immunol, 2021,12:773352. doi: 10.3389/fimmu.2021.773352.
［4］	Liu Z, Wang Q, Shao L, et al. The seborrheic dermatitis⁃distributed dermatomyositis: a facial cutaneous lesions sign associated with positive anti⁃MDA5 antibody［J］. J Cosmet Dermatol, 2022,21（3）:1309⁃1311. doi: 10.1111/jocd.14204.
［5］	Cabezas⁃Rodríguez I, Morante⁃Bolado I, Brandy⁃García A, et al. Anti⁃MDA5 dermatomyositis mimicking psoriatic arthritis［J］. Reumatol Clin （Engl Ed）, 2018,14（4）:224⁃226. doi: 10.1016/j.reuma.2016.10.010.
［6］	Zohar DN, Seluk L, Yonath H, et al. Anti⁃MDA5 positive dermatomyositis associated with rapidly progressive interstitial lung disease and correlation between serum ferritin level and treatment response［J］. Mediterr J Rheumatol, 2020,31（1）:75⁃77. doi: 10.31138/mjr.31.1.75.
［7］	Peng QL, Zhang YM, Liang L, et al. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis［J］. Clin Exp Immunol, 2020,199（3）:314⁃325. doi: 10.1111/cei.13404.
［8］	Sato S, Masui K, Nishina N, et al. Initial predictors of poor survival in myositis⁃associated interstitial lung disease: a multicentre cohort of 497 patients［J］. Rheumatology （Oxford）, 2018,57（7）:1212⁃1221. doi: 10.1093/rheumatology/key060.
［9］	Nagashima T, Kamata Y, Iwamoto M, et al. Liver dysfunction in anti⁃melanoma differentiation⁃associated gene 5 antibody⁃positive patients with dermatomyositis［J］. Rheumatol Int, 2019,39（5）:901⁃909. doi: 10.1007/s00296⁃019⁃04255⁃2.
［10］	Yamasaki Y, Kobayashi N, Akioka S, et al. Clinical impact of myositis⁃specific autoantibodies on long⁃term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study［J］. Rheumatology （Oxford）, 2021,60（10）:4821⁃4831. doi: 10. 1093/rheumatology/keab108.
［11］	Labrador⁃Horrillo M, Martinez MA, Selva⁃O′Callaghan A, et al. Anti⁃MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis［J］. J Immunol Res, 2014,2014:290797. doi: 10.1155/2014/290797.
［12］	Sato S, Murakami A, Kuwajima A, et al. Clinical utility of an enzyme⁃linked immunosorbent assay for detecting anti⁃melanoma differentiation⁃associated gene 5 autoantibodies［J］. PLoS One, 2016,11（4）:e0154285. doi: 10.1371/journal.pone.015 4285.
［13］	Nakashima R, Mimori T. Anti⁃MDA5 （melanoma differentiation⁃associated gene 5） antibody and dermatomyositis with rapidly progressive interstitial pneumonia［J］. Nihon Rinsho Meneki Gakkai Kaishi, 2013,36（2）:71⁃76. doi: 10.2177/jsci.36.71.
［14］	Matsuda KM, Yoshizaki A, Kuzumi A, et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti⁃melanoma differentiation⁃associated gene 5 antibody⁃positive dermatomyositis［J］. J Dermatol, 2020,47（5）:483⁃489. doi: 10.1111/1346⁃8138.15274.
［15］	Kahn JS, Deverapalli SC, Rosmarin DM. JAK⁃STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis［J］. Int J Dermatol, 2018,57（8）:1007⁃1014. doi: 10.1111/ijd.14064.
［16］	Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus⁃Kinase inhibitor tofacitinib ⁃ a report of two cases［J］. J Autoimmun, 2019,100:131⁃136. doi: 10.1016/j.jaut.2019.03.003.
［17］	Le Voyer T, Gitiaux C, Authier FJ, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study［J］. Rheumatology （Oxford）, 2021,60（12）:5801⁃5808. doi: 10.1093/rheumatology/keab116.
［18］	Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis⁃associated interstitial lung disease［J］. N Engl J Med, 2019,381（3）:291⁃293. doi: 10.1056/NEJMc1900045.
［19］	Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines［J］. Hematology Am Soc Hematol Educ Program, 2012,2012:7⁃12. doi: 10.1182/asheducation⁃2012.1.7.
［20］	Takahashi R, Yoshida T, Morimoto K, et al. Successful treatment of anti⁃MDA5 antibody⁃positive dermatomyositis⁃associated rapidly progressive⁃interstitial lung disease by plasma exchange: two case reports［J］. Clin Med Insights Case Rep, 2021,14:1179547 6211036322. doi: 10.1177/11795476211036322.
［21］	Endo Y, Koga T, Suzuki T, et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti⁃MDA5 antibody⁃positive dermatomyositis: a case report［J］. Medicine （Baltimore）, 2018,97（15）:e0436. doi: 10.1097/MD.00 00000000010436.
［22］	Kagawa H, Tsujino K, Yamamoto Y, et al. Acute lung injury after plasma exchange in a patient with anti⁃MDA5 antibody⁃positive, rapidly progressive, interstitial lung disease：a case report［J］. Respir Med Case Rep, 2020,29:101016. doi: 10.1016/j.rmcr. 2020.101016.
［23］	Scirocco C, Gubbiotti A, Sebastiani A, et al. Rituximab in antimelanoma differentiation⁃associated protein⁃5 dermato⁃myositis with interstitial lung disease［J］. Case Rep Rheumatol, 2020,2020:8145790. doi: 10.1155/2020/8145790.
［24］	Mao MM, Xia S, Guo BP, et al. Ultra⁃low dose rituximab as add⁃on therapy in anti⁃MDA5⁃positive patients with polymyositis /dermatomyositis associated ILD［J］. Respir Med, 2020,172:105983. doi: 10.1016/j.rmed.2020.105983.
［25］	Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis［J］. Arthritis Res Ther, 2007,9 Suppl 2（Suppl 2）:S2. doi: 10.1186/ar2186.
［26］	Min HK, Kim HR, Lee SH, et al. Refractory digital ulcers treated by botulinum toxin and endothelin receptor⁃1 antagonist in anti⁃MDA5⁃antibody⁃positive dermatomyositis［J］. J Clin Neurol, 2020,16（1）:160⁃162. doi: 10.3988/jcn.2020.16.1.160.
［27］	Collantes⁃Rodríguez C, Jiménez⁃Gallo D, Ossorio⁃García L, et al. Image gallery: cutaneous ulcers in anti⁃MDA5 dermatomyositis successfully treated with sildenafil［J］. Br J Dermatol, 2020,182（1）:e1. doi: 10.1111/bjd.18376.
［28］	Leclair V, Labirua⁃Iturburu A, Lundberg IE. Successful lung transplantation in a case of rapidly progressive interstitial lung disease associated with antimelanoma differentiation⁃associated gene 5 antibodies［J］. J Rheumatol, 2018,45（4）:581⁃583. doi: 10.3899/jrheum.171047.
［29］	Deitchman AR, Kalchiem⁃Dekel O, Todd N, et al. Rapidly progressive interstitial lung disease due to anti⁃melanoma differentiation associated protein⁃5 requiring a bilateral lung transplant, and complicated by kennel cough［J］. Respir Med Case Rep, 2019,28:100886. doi: 10.1016/j.rmcr.2019.100886.

[1]	Yang Ji, Xu Xinzhi, Li Ming. Early diagnosis of dermatomyositis and early recognition of visceral injury [J]. Chinese Journal of Dermatology, 2023, 56(2): 161-164.
[2]	Ye Jiaqi, Chai Weimin, Zheng Jie, Cao Hua. Evaluation of dermatomyositis complicated by interstitial lung disease based on skin lesions, serum biomarkers and radiological features [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220388-e20220388.
[3]	Zhang Shimin, Hu Yunyun, Zhao Xiaoqing, Du Lianjun, Cao Hua, Zheng Jie. Application of imaging techniques in diagnosis and severity assessment of dermatomyositis [J]. Chinese Journal of Dermatology, 2022, 55(7): 637-640.
[4]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[5]	Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279.
[6]	Cao Hua, Zheng Jie . Evolution of diagnostic criteria for clinically amyopathic dermatomyositis [J]. Chinese Journal of Dermatology, 2022, 55(11): 1008-1013.
[7]	Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases. Chinese Expert consensus on the diagnosis and treatment of adult dermatomyositis （2022） [J]. Chinese Journal of Dermatology, 2022, 55(11): 939-949.
[8]	Yang Ji, Xu Xinzhi, Li Ming. Pseudoangioedema: a new type of skin lesions of dermatomyositis [J]. Chinese Journal of Dermatology, 2022, 55(11): 1019-1020.
[9]	Autoimmune Disease Group, China Dermatologist Association. Chinese expert consensus on cyclophosphamide for the treatment of autoimmune dermatoses [J]. Chinese Journal of Dermatology, 2021, 54(9): 765-770.
[10]	Yang Ji, Xu Xinzhi, Li Ming. Seborrheic dermatitis-distributed dermatomyositis: a special type of dermatomyositis [J]. Chinese Journal of Dermatology, 2021, 54(7): 639-641.
[11]	Yang Changzhi, Zhang Xiaoping, Yang Ziliang, Zhou Naihui, Zhu Liping, Shao Kai, Zhu Tingting, Yu Xiuqin. Association of antinuclear antibody status with clinical features and malignancy risk in adult patients with dermatomyositis [J]. Chinese Journal of Dermatology, 2021, 54(6): 480-484.
[12]	Hua Weiwei, Gong Chunyan. Application of JAK inhibitors in the treatment of refractory dermatomyositis [J]. Chinese Journal of Dermatology, 2021, 54(3): 264-267.
[13]	Committee on Autoimmune Diseases, China Dermatologist Association. Azathioprine in the treatment of immune?related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2021, 54(2): 116-121.
[14]	Committee on Autoimmune Diseases, China Dermatologist Association. Mycophenolate mofetil in the treatment of immune?related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2020, 53(11): 869-874.
[15]	Xue Ke, Quan Cheng, Zhao Qian, Diao Licheng, Chen Mengya, Zhu Xuemei, Zheng Jie, Cao Hua, Li Hao . Differentially expressed genes in peripheral blood of patients with dermatomyositis complicated by interstitial lung disease or malignant tumors [J]. Chinese Journal of Dermatology, 2020, 53(1): 23-29.

Progress in treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［29］

Related Articles 15

Metrics

Comments

Recommended 10